ACHV

Achieve Life SciencesC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$10.00

+59.5% vs current

Most likely

Base case

45%

Probability

Target price

$5.50

-12.3% vs current

B-

Bear case

30%

Probability

Target price

$2.25

-64.1% vs current

AI sentiment snapshot

Latest data as of 2026-06-19

AI commentary

Recent coverage tone has been mildly constructive because the May 12, 2026 company update paired a large financing with manufacturing-transition progress and commercial buildout, but the setup into June 20, 2026 is still dominated by the expected CRL and resubmission timing rather than by clean operating momentum. Coverage is thin, no reliable post-print analyst revision set is in the packet, and no usable social signal is available, so this remains a monitoring-style setup rather than a high-conviction bullish call.

RankAlpha Sentiment Codex - 2026-06-19

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-20eventJune 20, 2026 FDA action is likely a manufacturing-driven CRL rather than a product-data decisionHigh impact

Management said the prior third-party manufacturer received an OAI classification tied to general cGMP matters not specific to cytisinicline, and Achieve expects a Complete Response Letter on or before the June 20, 2026 PDUFA date, delaying approval but not necessarily changing the core efficacy thesis [#SEC-8K-2026-05-12] [#10-Q-2026-05-12].

2026-11-15catalystQ4 2026 NDA resubmission with Adare is the main re-rating pathHigh impact

Achieve said it intends to resubmit the NDA in Q4 2026 with Adare as the new primary commercial manufacturing partner after completing analytical transfer, first engineering batch work, and testing qualification; successful remediation would be the clearest de-risking step toward the stated H1 2027 U.S. launch plan [#SEC-8K-2026-05-12].

2026-12-31catalystFinancing plus ORCA-V2 funding preserves second-indication optionalityHigh impact

The May 12, 2026 company update said the private placement brought $180.0 million gross, with milestone warrants on approval, and that proceeds are intended to fund commercialization and the ORCA-V2 Phase 3 trial for e-cigarette cessation; that supports runway and keeps the vaping program alive, though it remains secondary to fixing the smoking-cessation NDA path [#SEC-8K-2026-05-12] [#10-Q-2026-05-12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-19 • Updated nightlySource: Internal modelMethodology